Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Larry Weathers

Cardiovascular Disease Rogers, AR Medical Doctor

NPI 1770635047 CMS profile 34590

2708 Rife Medical Ln, Suite 220, Rogers, AR 72758

Open in the dashboard

General payments

$6,084

398 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Larry Weathers of Rogers, AR is reported in the CMS Open Payments database as having received $6,084 across 398 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $46 2
2023 General $108 6
2022 General $1,249 85
2021 General $1,524 105
2020 General $1,191 73
2019 General $1,965 127

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Larry Weathers
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Larry Weathers were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Larry Weathers Cardiovascular Disease median Middle half National median
2019 $1,965 $450 $127–$1,392 $163
2020 $1,191 $242 $77–$751 $114
2021 $1,524 $335 $101–$1,037 $132
2022 $1,249 $395 $121–$1,211 $149
2023 $108 $443 $136–$1,283 $160
2024 $46 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Amarin Pharma Inc. $627 31 payments
  2. Novartis Pharmaceuticals Corporation $585 37 payments
  3. Janssen Pharmaceuticals, Inc $580 80 payments
  4. Abbott Laboratories $540 24 payments
  5. Amgen Inc. $533 41 payments
  6. AstraZeneca Pharmaceuticals LP $490 21 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $462 34 payments
  8. Pfizer Inc. $448 44 payments
  9. HeartFlow, Inc. $444 6 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $208 15 payments
  11. Other $1,167 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $6,014 396 payments
  2. Education $69 2 payments
Products named General payments · program years 2019–2024
  1. XARELTO $580 80 payments
  2. Repatha $533 41 payments
  3. Vascepa $513 25 payments
  4. ENTRESTO $493 31 payments
  5. JARDIANCE $462 34 payments
  6. ELIQUIS $334 34 payments
  7. BRILINTA $304 8 payments
  8. LifeVest $208 15 payments
  9. Corlanor $192 14 payments
  10. VERQUVO $164 11 payments
  11. Other $2,260 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

322

Median for Cardiology: 2,533

Drug cost

$57,221

Median for Cardiology: $485,213

Branded share of claims

33.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 33 $37,300
Xarelto Rivaroxaban Brand 16 $17,506
Atorvastatin Calcium Generic 69 $652
Chlorthalidone Generic 21 $482
Metoprolol Succinate Generic 20 $289
Clopidogrel Clopidogrel Bisulfate Brand 33 $201
Amlodipine Besylate Generic 30 $159
Carvedilol Generic 18 $120
Metoprolol Tartrate Generic 11 $107
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 11 $94

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Records

398 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record